In this interview, we discuss a study of sex differences in the tolerability of anti–programmed death 1 immunotherapy among patients with metastatic melanoma.
Narjust Duma, MD
Advertisement
Articles by Narjust Duma, MD
Advertisement
Latest Updated Articles
Narjust Duma on How Gender Affects the Tolerability of ImmunotherapyPublished: July 15th 2018 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Belzutifan Plus Lenvatinib Improves PFS/ORR in Advanced Pretreated RCC
2
JSKN003 Receives FDA Fast Track Designation in Advanced PROC
3
Response Rates Show Promise in Phase 1 trial Involving ASCT in Metastatic PDAC
4
Case 2: Patient With High-Risk RRMM Relapsing After BCMA CAR T-Cell Therapy
5
